Jefferson Einstein Philadelphia Hospital

Running trials

• Recruiting

  Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

  NCT07234968· Thomas Jefferson University· Source

• Active, not recruiting

  Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

  NCT06538038· PrECOG, LLC.· Source

• Recruiting

  A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  NCT06308978· Phase 1· Fate Therapeutics· Source

• Active, not recruiting

  An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

  NCT06117891· Bayer· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· Phase 3· NRG Oncology· Source

• Active, not recruiting

  ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

  NCT05064553· Exact Sciences Corporation· Source

• Active, not recruiting

  Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  NCT04513717· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

  NCT03970343· Impulse Dynamics· Source

• Active, not recruiting

  Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

  NCT07224347· Anne Murray· Source

• Active, not recruiting

  Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456· Abbott Medical Devices· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT01708954· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

  NCT00098475· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ANCA-associated vasculitis1 recruiting
• Bladder cancer1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Lupus (SLE)1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Kowa Research Institute, Inc.· Source

• Terminated

  Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

  NCT05582018· Techsomed Medical Technologies LTD· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

  NCT05143177· Phase 2/3· REDNVIA Co., Ltd.· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Osteonecrosis (avascular necrosis)5 works · 0 trials
• Antiphospholipid syndrome3 works · 0 trials